January 2019
-
Media ReleaseNovartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018Full year net sales up 5% (cc1, +6% USD) driven by strong performance of growth drivers: Pharmaceuticals BU grew 7% (cc) driven by Cosentyx USD 2.8 billion (+36% cc) and Entresto USD 1.0 billion (+…
-
Media ReleaseSandoz Inc. launches SYMJEPI™ (epinephrine) in the USPrinceton, New Jersey, January 16, 2019 – Sandoz Inc. (Sandoz), a Novartis division, today announced the US market introduction of SYMJEPI™ (epinephrine) 0.3 mg Injection for the emergency treatment…
-
Media ReleaseSandoz selects three finalists for Healthcare Access Challenge (Sandoz HACk) from over 400 global entriesCompetition generated ideas from more than 400 entrants in 80 countries – three shortlisted entrants from Uganda, the US and the Netherlands Three finalists shared innovative uses of artificial…
-
Media ReleaseSandoz and Pear Therapeutics Announce US Launch of reSET-OTM to Help Treat Opioid Use DisorderreSET-O(TM)* is the first US FDA-cleared prescription digital therapeutic for patients with Opioid Use Disorder Cleared by the FDA in December, reSET-O is available immediately As part of a broader…
December 2018
-
Media ReleaseSandoz enters into commercialization and supply agreement for insulin biosimilars, anticipating growing demand as diabetes burden risesAgreement covers biosimilar insulins in early and clinical development for the top three selling branded insulins by sales: glargine, lispro and aspart Over 400 million people worldwide have…
-
Media ReleaseSandoz teams up to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)Strategic collaboration agreement with Curetis subsidiary Ares Genetics to develop digital platform for development and life-cycle management of antibiotics Program will combine established…
-
Media ReleaseSandoz Inc. and Pear Therapeutics Obtain FDA Clearance for reSET-O(TM) to Treat Opioid Use DisorderreSET-OTM is the first FDA-cleared Prescription Digital Therapeutic (PDT) for patients with Opioid Use Disorder Pear Therapeutics is leading the development of a new therapeutic class with two FDA-…
-
Media ReleaseSandoz certified Top Employer Asia Pacific 2019Sandoz has been certified by the Top Employers Institute for its exceptional employee offerings in Asia Pacific (APAC) The annual, international research undertaken by the Top Employers Institute…
November 2018
-
Media ReleaseSandoz receives eighth European Commission approval for a biosimilar with Ziextenzo® (pegfilgrastim)Biosimilar Ziextenzo® (pegfilgrastim), a long-acting version of supportive oncology medicine filgrastim, is now approved for use in all reference medicine indications1 Ziextenzo is indicated to…
-
Media ReleaseSandoz and Pear Therapeutics announce launch of reSET® for treatment of patients with Substance Use DisorderreSET® is the first and only FDA-authorized prescription digital therapeutic for Substance Use Disorder (SUD) Adding reSET to outpatient therapy significantly improved abstinence in substances of…
-
Media ReleaseSandoz commits to practical and scalable solutions to combat growing global threat of antimicrobial resistance (AMR)Antibiotics are the cornerstone of modern medicine, but AMR represents an increasingly serious threat to global public health1 Sandoz, as the world’s leading provider of high-quality antibiotics, is…
-
Media ReleaseSandoz decides not to pursue US biosimilar rituximab; will focus on robust biosimilar portfolio for unmet access and sustainability needsDecision follows FDA request for additional information to complement submission for biosimilar rituximab Sandoz stands behind safety, efficacy and quality of our biosimilar rituximab, which is…